If the vaccine does not protect individuals from infection, those who have been vaccinated could falsely believe they are protected.
Articles on Vaccine development
Displaying 41 - 60 of 74 articles
The race is on to develop a vaccine for the COVID-19 coronavirus. Australian researchers are leading several major clinical trials that might help bring an end to the deadly disease.
Immunosenescence — the decline of immune system function with age — means that vaccines are not as effective in older adults, the demographic most susceptible to many diseases, including COVID-19.
The experimental vaccine stimulates the creation of antibodies. Now we need to show that these effectively protect us from the coronavirus.
There isn’t enough clinical research being done in Africa. This has had a lot of repercussions in terms of the timing when interventions become available and effective in high income countries.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
It usually takes 10 years for a new vaccine to complete clinical trials, but we’ve been promised a COVID-19 vaccine in 12 to 18 months. Even if such fast-tracked development is possible, is it wise?
Politicians are throwing billions of dollars at coronavirus vaccine trials, but the real cost of research is the one thing we’re lacking – time.
As most of the world early awaits a vaccine for COVID-19, a smaller group of people scoffs. They could spell real trouble in the effort to build widespread immunity.
A test that detects antibodies against the coronavirus behind COVID-19 would reveal those people who have already encountered the virus - and therefore who might be ok to resume normal life.
Researchers around the world are working hard on developing a vaccine – but the process may still take 12-18 months. Here’s why.
We urgently need a vaccine for COVID-19 but exposing humans to a vaccine candidate that hasn’t undergone the usual safety assessments is risky.
Scientists are pursuing several different avenues to develop a vaccine for the novel coronavirus, but the process could take years.
Researchers around the world are working together to control the coronavirus outbreak, now known as COVID-19. This is what’s behind the global effort to develop a vaccine.
A challenge in eradicating polio comes from a version of the vaccine itself, which relies on live but attenuated virus. Rationally designing a new vaccine could help get rid of polio once and for all.
Lung plague attacks cattle causing disease and death, and more than US$60 million in losses annually in Africa. A new vaccine could prevent the disease.
Vaccines need to be kept cold to remain effective. A lack of power in remote areas makes this difficult, reducing the reach of the life-saving pharmaceuticals.
Manufacturing one of the world’s most important vaccines will have several benefits for South Africa.
Flu virus mutates so quickly that one year’s vaccine won’t work on the next year’s common strains. But rational design – a new way to create vaccines – might pave the way for more lasting solutions.
Current plans to eradicate polio mean keeping the virus alive – and risk restarting the epidemic.
Top contributors
-
Professor of Immunology and Associate Dean, Research and Graduate Studies, University of Guelph
-
Associate Professor of Viral Immunology, Department of Pathobiology, University of Guelph
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Professor, School of Population Health, UNSW
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Vaccine Knowledge Project Manager, University of Oxford
-
Clinician-scientist, Laboratory Medicine and Pathobiology, University of Toronto
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, RMIT University
-
Associate Professor of Bioethics, University of Portsmouth
-
Infectious Diseases Specialist and Clinical Professor, University of Tasmania
-
Ph.D. Student in Microbiology and Immunology, Vanderbilt Vaccine Center, Vanderbilt University
-
Senior Project Manager, Jenner Institute, University of Oxford
-
Ph.D. Candidate in Chemical & Physical Biology, Vanderbilt Vaccine Center, Vanderbilt University